Needham analyst Gil Blum reiterated a Buy rating on Celcuity (CELC – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $9.58.
According to TipRanks, Blum is an analyst with an average return of -15.9% and a 35.06% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Selecta Biosciences, and CTI BioPharma.
Celcuity has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $14.40 and a one-year low of $4.81. Currently, Celcuity has an average volume of 77.05K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.
Read More on CELC:
